Maybest Science and Technology Development

Beijing Maybest Science and Technology Development is a clinical-stage Chinese biotechnology company dedicated to developing next-generation therapies for metabolic disorders and cancer. The company is particularly recognized for its advanced pipeline of multi-target peptide agonists, including dual and triple agonists targeting the GLP-1, GIP, and glucagon receptors. These candidates are designed to treat prevalent conditions such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). By utilizing its proprietary peptide engineering and optimization platform, Maybest aims to create highly potent and long-acting biologics with improved safety profiles. The firm's lead candidate, MB-11078, is a triple receptor agonist currently undergoing clinical evaluation to provide superior weight loss efficacy compared to existing treatments.